Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Dluzen Dean; Horstink Martin

Endocrine

2003

2003-06

In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal- nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease.

Humans; Sex Characteristics; Estrogens/*pharmacology; *Neuroprotective Agents; Basal Ganglia Diseases/prevention & control; Dopamine/*physiology; Neostriatum/cytology/drug effects/*physiology; Parkinson Disease/pathology/prevention & control; Substantia Nigra/cytology/drug effects/*physiology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

67–75

1

21